BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Shares of Biogen Inc. BIIB inched 0.04% higher to $160.92 Wednesday, on what proved to be an all-around positive trading ...

We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to our team,” said John Evans, chief executive officer at Beam.

The article summarizes current notable health news, including Biogen's Alzheimer's drug growth, mysterious disease in Congo, ...

Shares of Biogen Inc. BIIB shed 2.06% to $160.85 Tuesday, on what proved to be an all-around mixed trading session for the ...

The article summarizes recent developments in the health sector, including Biogen's Alzheimer's drug growth, Idaho's abortion ...

On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

Palantir Technologies leads the list of a half dozen companies that could be added to the $26 trillion Nasdaq 100 index at ...

On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.